Volume 6,Issue 3
Lung Adenocarcinoma Gene Mutation in Koreans Detection Using Next Generation Sequence Analysis Technique and Analysis of Concordance with Existing Genetic Test Methods
Lung adenocarcinoma accounts for about 40% of all lung cancers. With the recent development of gene profiling technology, studies on mutations in oncogenes and tumor suppressor genes, which are important for the development and growth of tumors, have been actively conducted. Companion diagnosis using next-generation sequencing helps improve survival with targeted therapy. In this study, formalin-fixed paraffinembedded tissues of non-small cell lung cancer patients were subjected to hematoxylin and eosin staining to detect genetic mutations that induce lung adenocarcinoma in Koreans. Immunohistochemical staining was also performed to accurately classify lung adenocarcinoma tissues. Based on the results, next-generation sequencing was applied to analyze the types and patterns of genetic mutations, and the association with smoking was established as the most representative cause of lung cancer. The results of next-generation sequencing analysis confirmed the single nucleotide variations, copy number variations, and gene rearrangements. To validate the reliability of next-generation sequencing, we additionally performed the existing genetic testing methods (polymerase chain reaction-epidermal growth factor receptor, immunohistochemistry-anaplastic lymphoma kinase [D5F3], and fluorescence in situ hybridization-receptor tyrosine kinase 1 tests) to confirm the concordance rates with the next-generation sequencing test results. This study demonstrates that next-generation sequencing of lung adenocarcinoma patients simultaneously identifies mutation.
1. Korea National Cancer Center, 2019, 2019 Cancer Registry Statistics Press Release, viewed, December 30, 2021, https://www.ncc.re.kr/cancerStatsView.ncc?bbsnum=578&searchKey=total&searchValue=&pageNum=1
2. Union for International Cancer Control, 2018, Global Cancer Data: GLOBOCAN 2018, viewed, September 12, 2018, https://www.uicc.org/news/global-cancer-data-globocan-2018
3. International Agency for Research on Cancer, 2022, Lung Cancer Awareness Month 2022, viewed, November 4, 2022, https://www.iarc.who.int/news-events/lung-cancer-awareness-month-2022/
4. El-Telbany A, Ma PC, 2012, Cancer Genes in Lung Cancer: Racial Disparities: Are There Any? Genes & Cancer, 3(7–8): 467–480. https://doi.org/10.1177/1947601912465177
5. Hirsch FR, Scagliotti GV, Mulshine JL, et al., 2017, Lung Cancer: Current Therapies and New Targeted Treatments. Lancet, 389(10066): 299–311. https://doi.org/10.1016/S0140-6736(16)30958-8
6. Goldstraw P, Ball D, Jett JR, et al., 2011, Non-Small-Cell Lung Cancer. Lancet, 378(9804): 1727–1740. https://doi.org/10.1016/S0140-6736(10)62101-0
7. Zappa C, Mousa SA, 2016, Non-Small Cell Lung Cancer: Current Treatment and Future Advances. Translational Lung Cancer Research, 5(3): 288–300. https://doi.org/10.21037/tlcr.2016.06.07
8. Chan BA, Hughes BG, 2015, Targeted Therapy for Non-Small Cell Lung Cancer: Current Standards and the Promise of the Future. Translational Lung Cancer Research, 4(1): 36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01
9. Van Allen EM, Wagle N, Stojanov P, et al., 2014, Whole-Exome Sequencing and Clinical Interpretation of Formalin-Fixed, Paraffin-Embedded Tumor Samples to Guide Precision Cancer Medicine. Nature Medicine, 20: 682–688. https://doi.org/10.1038/nm.3559
10. U.S. Food and Drug Administration, 2017, Premarket Approval: Next Generation Sequencing Oncology Panel, Somatic or Germline Variant Detection System, viewed, June 24, 2019, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019
11. Desai A, Menon SP, Dy GK, 2016, Alterations in Genes Other than EGFR/ALK/ROS1 in Non-Small Cell Lung Cancer: Trials and Treatment Options. Cancer Biology & Medicine, 13(1): 77–86. https://doi.org/10.28092/j.issn.2095-3941.2016.0008
12. Tsimberidou AM, Elkin S, Dumanois R, et al., 2020, Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 21(6): 477–481. https://doi.org/10.1016/j.cllc.2020.05.029
13. Einaga N, Yoshida A, Noda H, et al., 2017, Assessment of the Quality of DNA from Various Formalin-Fixed Paraffin-Embedded (FFPE) Tissues and the Use of this DNA for Next-Generation Sequencing (NGS) with no Artifactual Mutation. PLoS ONE, 12(5): e0176280. https://doi.org/10.1371/journal.pone.0176280
14. Osmani L, Askin F, Gabrielson E, et al., 2018, Current WHO Guidelines and the Critical Role of Immunohistochemical Markers in the Subclassification of Non-Small Cell Lung Carcinoma (NSCLC): Moving from Targeted Therapy to Immunotherapy. Seminars in Cancer Biology, 52(Pt 1): 103–109. https://doi.org/10.1016/j.semcancer.2017.11.019
15. Uruga H, Mino-Kenudson M, 2018, ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-Positive NSCLC Patients. Pharmacogenomics and Personalized Medicine, 2018: 147–155. https://doi.org/10.2147/PGPM.S156672
16. Myers DJ, Wallen JM, 2013, Lung Adenocarcinoma, StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK519578/
17. The Cancer Genome Atlas Research Network, 2014, Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature, 511: 543–550. https://doi.org/10.1038/nature13385
18. Yatabe Y, Kerr KM, Utomo A, et al., 2015, EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey. Journal of Thoracic Oncology, 10(3): 438–445. https://doi.org/10.1097/JTO.0000000000000422
19. Kawaguchi T, Matsumura A, Fukai S, et al., 2010, Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status are Independent Favorable Prognostic Factors for Overall Survival in Non-Small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases. Journal of Thoracic Oncology, 5(7): 1001–1010. https://doi.org/10.1097/JTO.0b013e3181e2f607
20. Chun YJ, Choi JW, Hong MH, et al., 2019, Molecular Characterization of Lung Adenocarcinoma from Korean Patients Using Next Generation Sequencing. PLoS ONE, 14(11): e0224379. https://doi.org/10.1371/journal.pone.0224379
21. Husgafvel-Pursiainen K, Boffetta P, Kannio A, et al., 2000, p53 Mutations and Exposure to Environmental Tobacco Smoke in a Multicenter Study on Lung Cancer. Cancer Research, 60: 2906–2911.
22. Kohno T, Nakaoku T, Tsuta K, et al., 2015, Beyond ALK-RET, ROS1 and Other Oncogene Fusions in Lung Cancer. Translational Lung Cancer Research, 4(2): 156–164. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11
23. Cao B, Wei P, Liu Z, et al., 2015, Detection of Lung Adenocarcinoma with ROS1 Rearrangement by IHC, FISH, and RT-PCR and Analysis of Its Clinicopathologic Features. OncoTargets and Therapy, 2016: 131–138. https://doi.org/10.2147/OTT.S94997